Pharmacology Core

药理学核心

基本信息

批准号：
8326902
负责人：
Angela D Kashuba
金额：
$ 22.61万
依托单位：
UNIV OF NORTH CAROLINA CHAPEL HILL
依托单位国家：
美国
项目类别：
财政年份：
2011
资助国家：
美国
起止时间：
2011-07-08 至 2016-06-30
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/8326902
关键词：
Algorithms Analytical Chemistry Animal Model Animals Anti-Retroviral Agents Biological Biological Assay Biological Models Cell Culture Techniques Cells Clinical Clinical Pharmacology Clinical Trials Clinical Trials Design Data Development Dose Drug Exposure Drug Kinetics Frequencies HIV HIV Infections HIV-1 Human Industry Infection Lead Leadership Logistics Marketing Modeling Monkeys Mus North Carolina Outcome Pharmaceutical Preparations Pharmacology Plasma Plasma Cells Production Research Contracts Research Design Research Personnel Resources Role Sampling Screening procedure Techniques Testing Therapeutic Therapeutic Studies Tissues Toxic effect Toxicology Universities Validation Viral base collaboratory design drug development experience indexing mouse model nonhuman primate pharmacodynamic model pre-clinical preclinical study scale up simulation small molecule small molecule libraries success

项目摘要

The role of Preclinical and Clinical Pharmacology is to maximize the likelihood of success of an identified candidate, or to quickly remove a likely unsuccessful candidate from progressing into further testing. The primary objective of the Pharmacology Core (Core B) is to provide the investigators of the Martin Deianey Collaboratory to Eradicate HlV-1 Infection with the pharmacologic expertise to study therapeutic strategies that reduce the latent viral pool and animal model systems, and to evaluate the pharmacologic basis of viral persistence in humans. The Pharmacology Core will coordinate access to chemical libraries, assist with lead candidate production scale-up, coordinate animal toxicology studies, analyze biological matrices for drug concentrations (both antiretroviral and induction/eradication compounds), provide pharmacokinetic/ pharmacodynamic (PK/PD) modeling for optimal dose and dose frequency selection, and perform trial simulation to optimize design and sampling strategies. This Core will participate in all aspects of drug development for identifying and progressing lead induction/eradication candidates. The Core leadership team (Drs. Kashuba and Tan) has over 20 years combined experience in preclinical and clinical pharmacology, analytical chemistry, and Core management, and are well-suited to support the projects in the Collaboratory. This results in a Core which combines academic and industry resources to synergize strengths.

临床前和临床药理学的作用是最大程度地提高成功的成功的可能性候选人，或迅速删除可能失败的候选人进入进一步的测试。这药理学核心（核心B）的主要目标是为马丁·迪亚尼（Martin Deianey）的研究人员提供与药理学专业知识中消除HLV-1感染的合作，以研究治疗策略这减少了潜在病毒池和动物模型系统，并评估病毒的药理基础人类的持久性。药理学核心将协调对化学库的访问，协助铅候选生产规模，协调动物毒理学研究，分析药物的生物基质浓度（抗逆转录病毒和诱导/根除化合物），提供药代动力学/ 用于最佳剂量和剂量频率选择的药效学（PK/PD）建模，并进行试验模拟以优化设计和采样策略。该核心将参与药物的各个方面确定和进步的铅诱导/消除候选者的开发。核心领导团队（Kashuba和Tan博士）拥有20多年的临床前和临床经验药理学，分析化学和核心管理，非常适合支持这些项目协作。这导致了结合学术和行业资源以协同作用的核心优势。